CN108779168A - Hiv结合剂 - Google Patents

Hiv结合剂 Download PDF

Info

Publication number
CN108779168A
CN108779168A CN201680080738.0A CN201680080738A CN108779168A CN 108779168 A CN108779168 A CN 108779168A CN 201680080738 A CN201680080738 A CN 201680080738A CN 108779168 A CN108779168 A CN 108779168A
Authority
CN
China
Prior art keywords
seq
bonding agent
ser
antibody
hiv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680080738.0A
Other languages
English (en)
Chinese (zh)
Inventor
G·潘塔莱奥
A·兰扎韦基亚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vodios University Hospital Center
Institute for Research in Biomedicine IRB
Original Assignee
Vodios University Hospital Center
Institute for Research in Biomedicine IRB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vodios University Hospital Center, Institute for Research in Biomedicine IRB filed Critical Vodios University Hospital Center
Publication of CN108779168A publication Critical patent/CN108779168A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN201680080738.0A 2015-12-05 2016-12-05 Hiv结合剂 Pending CN108779168A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562263618P 2015-12-05 2015-12-05
US62/263,618 2015-12-05
PCT/IB2016/057367 WO2017093985A1 (en) 2015-12-05 2016-12-05 Hiv binding agents

Publications (1)

Publication Number Publication Date
CN108779168A true CN108779168A (zh) 2018-11-09

Family

ID=57629603

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680080738.0A Pending CN108779168A (zh) 2015-12-05 2016-12-05 Hiv结合剂

Country Status (6)

Country Link
US (2) US10730933B2 (enExample)
EP (1) EP3383902A1 (enExample)
JP (1) JP2019509046A (enExample)
CN (1) CN108779168A (enExample)
CA (1) CA3045756A1 (enExample)
WO (1) WO2017093985A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10730933B2 (en) 2015-12-05 2020-08-04 Centre Hospitalier Universitaire Vaudois HIV binding agents
WO2020012435A1 (en) * 2018-07-13 2020-01-16 Lausanne University Hospital Hiv binding agents
WO2020082045A1 (en) * 2018-10-19 2020-04-23 University Of Maryland, College Park Multispecfic anti-hiv antibodies
JP7678790B2 (ja) * 2019-07-15 2025-05-16 ローザンヌ ユニヴァーシティ ホスピタル Ｈｉｖ結合剤
CN115963260B (zh) * 2022-06-27 2025-05-23 珠海碳云晶芯智能科技有限公司 多肽芯片及其在艾滋病诊断产品制备中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001024810A1 (en) * 1999-10-05 2001-04-12 Epimmune Inc. Inducing cellular immune responses to human immunodeficiency virus-1 using peptide and nucleic acid compositions
US20120269821A1 (en) * 2009-10-16 2012-10-25 Haynes Barton F Hiv-1 antibodies
CN104080805A (zh) * 2011-11-07 2014-10-01 美国政府健康及人类服务部 gp41中和性抗体及其用途

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DK169582B1 (da) 1986-06-23 1994-12-12 Squibb Bristol Myers Co Humant monoklonalt antistof, der er i stand til at reagere med en epitop på LAV/HTLV-III kappeglycoproteinet gp41, cellelinier, som producerer sådant antistof, farmaceutisk præparat indeholdende antistoffet samt fremgangsmåde til bestemmelse af nærværelsen af LAV/HTLV-III i en biologisk prøve og fremgangsmåde til separering af specifikke antigendeterminanter af LAV/HTLV-III under anvendelse af ant
US5087557A (en) 1986-06-23 1992-02-11 Genetic Systems Corporation Human monoclonal antibody to lymphadenopathy-associated virus
EP0681026A1 (en) 1987-03-02 1995-11-08 Whitehead Institute For Biomedical Research Recombinant mycobacterial vaccine
US5504005A (en) 1987-03-02 1996-04-02 Albert Einstein College Of Medicine Of Yeshiva University Recombinant mycobacterial vaccine
ATE135743T1 (de) 1987-11-13 1996-04-15 Hermann Katinger Monoklonale menschliche antikörper gegen hiv-i
US5831034A (en) 1987-11-13 1998-11-03 Hermann Katinger Human monoclonal anti-HIV-I-antibodies
AU608413B2 (en) 1988-03-30 1991-03-28 Abbott Laboratories Mouse monoclonal antibody (5-21-3) to human immunodeficiency virus gp41 protein
US5298419A (en) 1988-03-31 1994-03-29 The Arizona Board Of Regents On Behalf Of The University Of Arizona Human hybridomas and monoclonal antibodies which bind both gp41 and gp120 envelope proteins of human immunodeficiency virus
JPH0292298A (ja) 1988-09-30 1990-04-03 Olympus Optical Co Ltd Ｈｉｖ構成蛋白に対するモノクローナル抗体
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
JPH04505099A (ja) 1989-02-28 1992-09-10 ニューヨーク　ユニバーシィティ ヒト免疫不全ウイルスに対するヒトモノクローン抗体
US5731189A (en) 1989-02-28 1998-03-24 New York University Human monoclonal antibodies to human immunodeficiency virus
WO1990014363A1 (en) 1989-05-19 1990-11-29 Amgen Inc. Metalloproteinase inhibitor
US6008044A (en) 1989-08-24 1999-12-28 Bioclonetics Human monoclonal antibodies directed against the transmembrane glycoprotein (gp41) of human immunodeficiency virus-1 (HIV-1) and detection of antibodies against epitope (GCSGKLIC)
US5459060A (en) 1989-08-24 1995-10-17 Bioclonetics Incorporated Human monoclonal antibodies directed against the transmembrane glycoprotein (gp41) of human immunodeficiency virus-1 (HIV-1)
EP0511300A4 (en) 1990-01-16 1993-05-26 Replgien Corporation Monoclonal antibody specific for non-immunodominant epitope of hiv proteins
WO1991013157A1 (en) 1990-02-26 1991-09-05 Commonwealth Scientific And Industrial Research Organisation Shuttle plasmid for escherichia coli and mycobacteria
GB9015888D0 (en) 1990-07-19 1990-09-05 Smithkline Biolog Vectors
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
CA2089661C (en) 1990-08-29 2007-04-03 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2110682A1 (en) 1991-06-06 1992-12-10 Charles K. Stover Induction of ctl responses to foreign antigens expressed in mycobacteria
DE570357T1 (de) 1992-05-14 1994-07-28 Polimun Scientific Immunbiologische Forschungsgesellschaft Mbh, Wien Peptide, die Antikörper induzieren, die genetisch divergierende HIV-1 Isolationen neutralisieren.
US5652138A (en) 1992-09-30 1997-07-29 The Scripps Research Institute Human neutralizing monoclonal antibodies to human immunodeficiency virus
US6057421A (en) 1994-11-30 2000-05-02 Immpheron, Inc. Variable heavy and light chain regions of murine monoclonal antibody 1F7
EP0822941B1 (en) 1995-04-19 2002-06-12 Polymun Scientific Immunbiologische Forschung GmbH Monoclonal antibodies against hiv-1 and vaccines made thereof
NZ334941A (en) * 1996-10-10 2000-11-24 Probe Internat Methods for treating infections using proteins which induce an immune response in one animal species but not in another
JPH10226699A (ja) * 1996-12-10 1998-08-25 Fujirebio Inc Ｈｉｖ−１グループｏを認識するモノクローナル抗体及び該モノクローナル抗体を産生するハイブリドーマ
US20030118985A1 (en) 1997-05-14 2003-06-26 Hunt Jeffrey C. Mouse monoclonal antibody (5-21-3) to human immunodeficiency virus gp41 protein
CN1172717C (zh) 2000-08-18 2004-10-27 清华大学 一种治疗艾滋病的药物及其制备方法
KR20120004551A (ko) 2003-10-28 2012-01-12 어플라이드 머티어리얼스, 인코포레이티드 스크러버 박스 및 그 사용 방법
ATE516048T1 (de) 2004-06-01 2011-07-15 Merck Sharp & Dohme Mit hiv gp41 in wechselwirkung stehende menschliche antikörper
WO2006050219A2 (en) 2004-10-29 2006-05-11 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Broadly cross-reactive hiv-1 neutralizing human monoclonal antibodies
JP2012522520A (ja) * 2009-04-03 2012-09-27 デューク ユニバーシティー マウスモデル
EP2611465A4 (en) 2010-08-31 2014-06-04 Theraclone Sciences Inc ANTIBODIES FOR NEUTRALIZING THE HUMAN IMMUNODICITY VIRUS (HIV)
WO2015103549A1 (en) 2014-01-03 2015-07-09 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Neutralizing antibodies to hiv-1 env and their use
US10730933B2 (en) 2015-12-05 2020-08-04 Centre Hospitalier Universitaire Vaudois HIV binding agents

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001024810A1 (en) * 1999-10-05 2001-04-12 Epimmune Inc. Inducing cellular immune responses to human immunodeficiency virus-1 using peptide and nucleic acid compositions
US20120269821A1 (en) * 2009-10-16 2012-10-25 Haynes Barton F Hiv-1 antibodies
CN104080805A (zh) * 2011-11-07 2014-10-01 美国政府健康及人类服务部 gp41中和性抗体及其用途

Also Published As

Publication number Publication date
WO2017093985A1 (en) 2017-06-08
CA3045756A1 (en) 2017-06-08
EP3383902A1 (en) 2018-10-10
JP2019509046A (ja) 2019-04-04
US20190345234A1 (en) 2019-11-14
WO2017093985A4 (en) 2017-07-27
US20210009661A1 (en) 2021-01-14
US10730933B2 (en) 2020-08-04

Similar Documents

Publication Publication Date Title
US20220169733A1 (en) Immunological Reagents
ES3034233T3 (en) Non-blocking pd1 specific antibodies
AU2013229488B2 (en) Human binding molecules capable of binding to and neutralizing influenza B viruses and uses thereof
US20210009661A1 (en) HIV Binding Agents
JP2023534923A (ja) ＳＡＲＳ－ＣｏＶ－２を標的にする抗原結合分子
WO2020012435A1 (en) Hiv binding agents
US20250312438A1 (en) Humanized constructs, vaccines, and methods
JP7678790B2 (ja) Ｈｉｖ結合剤
US20250277003A1 (en) Glycosylated rbd and use thereof
US20240285753A1 (en) Epitope-scaffold immunogens for pancoronavirus vaccines
CN117062624A (zh) 抗covid-19中和单克隆抗体

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20181109

WD01 Invention patent application deemed withdrawn after publication